Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HLCS | P50747 | 5/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17652444 | 0.91 | TDP1 (0.63) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL13312995 | 0.90 | TDP1 (0.53) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL15255492 | 0.89 | TDP1 (0.56) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL903555 | 0.88 | TDP1 (0.61) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL13759596 | 0.87 | F2 (0.59) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL12102937 | 0.87 | F2 (0.59) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL2608510 | 0.87 | F2 (0.59) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL24637661 | 0.86 | F2 (0.60) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL12937922 | 0.86 | F2 (0.60) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL15315671 | 0.86 | F2 (0.60) | TDP1PKMMEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763995-B2 | Polymer conjugates of protegrin peptides | NEKTAR THERAPEUTICS (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-9433684-B2 | Conjugates of small-interfering nucleic acids | NEKTAR THERAPEUTICS (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160158311-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | NEKTAR THERAPEUTICS | 2016-06-09 | — | — | US | disclosed |
| US-9347054-B2 | Polymer factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9101670-B2 | Conjugates of an anti-TNF-α antibody | NEKTAR THERAPEUTICS (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | TDP1 3122/4885PKM 2951/4885MEN1 844/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | TDP1 3051/4885PKM 3125/4885MEN1 778/4885 |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | TDP1 2854/4885PKM 3973/4885MEN1 1549/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | TDP1 1186/4885PKM 4415/4885MEN1 1777/4885 |
| US-20100210505-A1 | POLYMER CONJUGATES OF GLP-1 | GLP1R, GIPR, NGLY1 | TDP1 1852/4885PKM 1900/4885MEN1 212/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | TDP1 1145/4885PKM 4331/4885MEN1 1731/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | TDP1 3122/4885PKM 2951/4885MEN1 844/4885 |
| US-20160158311-A1 | POLYMER CONJUGATES OF PROTEGRIN PEPTIDES | PSMG3, PSMB11, UBQLN1 | TDP1 3024/4885PKM 4283/4885MEN1 1753/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | TDP1 3149/4885PKM 3548/4885MEN1 290/4885 |
| US-20100130428-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | TDP1 3122/4885PKM 2951/4885MEN1 844/4885 |
| US-20100137511-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | TDP1 3122/4885PKM 2951/4885MEN1 844/4885 |
| US-20170035898-A1 | CONJUGATES OF AN IL-15 MOIETY AND A POLYMER | IL15, IL15RA, IL2 | TDP1 4118/4885PKM 3894/4885MEN1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.